Drugs / IL-2 (Aldesleukin)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05035407 Background | Mar 2022 → Jul 2025 | — | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-2 (Aldesleukin) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05035407 ↗ |
| Route | Intravenous | “as an intravenous bolus” NCT05035407 ↗ |